đŁ VC round data is live. Check it out!
- Public Comps
- C4 Therapeutics
C4 Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for C4 Therapeutics and similar public comparables like Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences and more.
C4 Therapeutics Overview
About C4 Therapeutics
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patientsâ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the bodyâs natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
Founded
2015
HQ

Employees
110
Website
Financials (LTM)
EV
$305M
Valuation Multiples
Start free trialC4 Therapeutics Financials
C4 Therapeutics reported last 12-month revenue of $30M.
In the same LTM period, C4 Therapeutics generated $27M in gross profit and had net loss of ($112M).
Revenue (LTM)
C4 Therapeutics P&L
In the most recent fiscal year, C4 Therapeutics reported revenue of $36M and EBITDA of ($103M).
C4 Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of (285%) and net margin of (292%).
Financial data powered by Morningstar, Inc.
C4 Therapeutics Stock Performance
C4 Therapeutics has current market cap of $482M, and enterprise value of $305M.
Market Cap Evolution
C4 Therapeutics' stock price is $4.36.
C4 Therapeutics share price decreased by 0.2% in the last 30 days, and increased by 204.9% in the last year.
C4 Therapeutics has an EPS (earnings per share) of $-0.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $305M | $482M | -0.5% | -0.2% | 65.8% | 204.9% | $-0.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialC4 Therapeutics Valuation Multiples
C4 Therapeutics trades at 10.0x EV/Revenue multiple, and (3.0x) EV/EBITDA.
EV / Revenue (LTM)
C4 Therapeutics Financial Valuation Multiples
As of June 3, 2026, C4 Therapeutics has market cap of $482M and EV of $305M.
C4 Therapeutics has a P/E ratio of (4.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified C4 Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


C4 Therapeutics Margins & Growth Rates
C4 Therapeutics decreased revenue by 36% but net profit grew by 16% in the last fiscal year.
In the most recent fiscal year, C4 Therapeutics reported EBITDA margin of (285%) and net margin of (292%).
C4 Therapeutics Margins
C4 Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
C4 Therapeutics Operational KPIs
C4 Therapeutics' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
C4 Therapeutics Competitors
C4 Therapeutics competitors include Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences, YungShin Global Holding, Synmosa Biopharma, Blau FarmacĂȘutica, CytoDyn, PKU Healthcare and Medigen Vaccine Biologics.
Most C4 Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 16.4x | 3.9x | (0.9x) | - | |||
| - | - | (1.7x) | (1.6x) | |||
| 1.3x | 2.1x | (0.8x) | (0.5x) | |||
| 3.6x | 3.9x | (21.8x) | 47.7x | |||
| 1.6x | - | 8.5x | - | |||
| 2.4x | - | 12.3x | - | |||
| 1.5x | 1.4x | 4.7x | 5.6x | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all C4 Therapeutics competitors and their valuation data. Start Free Trial | ||||||
C4 Therapeutics VC Funding History
Before going public, C4 Therapeutics raised $73M in total equity funding, across 1 round.
C4 Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout C4 Therapeutics
| When was C4 Therapeutics founded? | C4 Therapeutics was founded in 2015. |
| Where is C4 Therapeutics headquartered? | C4 Therapeutics is headquartered in United States. |
| How many employees does C4 Therapeutics have? | As of today, C4 Therapeutics has over 110 employees. |
| Who is the CEO of C4 Therapeutics? | C4 Therapeutics' CEO is Andrew J. Hirsch. |
| Is C4 Therapeutics publicly listed? | Yes, C4 Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of C4 Therapeutics? | C4 Therapeutics trades under CCCC ticker. |
| When did C4 Therapeutics go public? | C4 Therapeutics went public in 2020. |
| Who are competitors of C4 Therapeutics? | C4 Therapeutics main competitors include Prothena Corp., Kyverna Therapeutics, 4D Molecular Therapeutics, Assembly Biosciences, YungShin Global Holding, Synmosa Biopharma, Blau FarmacĂȘutica, CytoDyn, PKU Healthcare, Medigen Vaccine Biologics. |
| What is the current market cap of C4 Therapeutics? | C4 Therapeutics' current market cap is $482M. |
| What is the current revenue of C4 Therapeutics? | C4 Therapeutics' last 12 months revenue is $30M. |
| What is the current revenue growth of C4 Therapeutics? | C4 Therapeutics revenue growth (NTM/LTM) is (29%). |
| What is the current EV/Revenue multiple of C4 Therapeutics? | Current revenue multiple of C4 Therapeutics is 10.0x. |
| Is C4 Therapeutics profitable? | No, C4 Therapeutics is not profitable. |
| What is the current net income of C4 Therapeutics? | C4 Therapeutics' last 12 months net income is ($112M). |
| How many companies C4 Therapeutics has acquired to date? | C4 Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies C4 Therapeutics has invested to date? | C4 Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to C4 Therapeutics
Lists including C4 Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.